A new first line choice? Has clopidogrel superseded aspirin for secondary prevention following selected minor ischaemic strokes?
- 16 June 2026
- journal article
- Published by Wiley in Internal Medicine Journal
- Vol. 56 (7) , 1266-1267
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Clopidogrel May Be Superior to Aspirin as Maintenance Antiplatelet Monotherapy in Patients With Non-Cardioembolic Ischemic StrokeJournal of Stroke, 2025
- Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic modelHealth Technology Assessment, 2024
- The association of CYP2C19LoF alleles with adverse clinical outcomes in stroke patients taking clopidogrel: An updated meta‐analysisClinical and Translational Science, 2024
- Antiplatelet drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysisBMC Neurology, 2021
- Drugs in secondary stroke preventionAustralian Prescriber, 2021
- Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-AnalysisCardiovascular Therapeutics, 2019
- Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic AttackCirculation, 2017
- Clopidogrel vs. Aspirin Treatment on Admission Improves 5-Year Survival After a First-ever Acute Ischemic Stroke. Data from the Athens Stroke Outcome ProjectArchives of Medical Research, 2011
- Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysisThe American Journal of Medicine, 2004
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996